Actively Recruiting
BIFANG Evaluating Nasal Polyps and Symptoms in Chinese Adults with Chronic Rhinosinusitis Using Tezepelumab
Led by AstraZeneca · Updated on 2026-10-16
230
Participants Needed
34
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effects of tezepelumab in Chinese adults with chronic rhinosinusitis with nasal polyposis CRSwNP, focusing on nasal polyps score and symptom changes. This open-label, single-arm Phase 3b study aims to include about 230 participants across multiple centers in China, specifically targeting those with an eosinophilic inflammatory endotype as measured by the JESREC score. Participants will receive a fixed dose of 210 mg tezepelumab via subcutaneous injection every four weeks for 24 weeks, totaling six doses administered at study sites. This treatment period is designed to assess changes in nasal polyps and symptoms related to CRSwNP, including nasal congestion and sino-nasal outcomes. Throughout the study, participants will undergo regular assessments including nasal polyp scores, nasal congestion scores, symptom questionnaires, and lung function tests for those with asthma. Monitoring includes daily symptom tracking before and during treatment, scheduled evaluations up to week 24, and safety assessments. The studys primary outcomes focus on changes in nasal polyp scores and nasal congestion from baseline to week 24.
CONDITIONS
Brief Title
A Study to Investigate NPS and Symptoms in Chinese Adult Participants With CRSwNP Initiating Treatment With Tezepelumab
Research Team
A
AstraZeneca Clinical Study Information Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here